Law360, New York (April 26, 2006, 12:00 AM EDT) -- A small biotech company has won a permanent injunction against Eli Lilly & Co. in a two-year battle waged over a patent application for technology used to convert injectable-only drugs into ones that can be taken orally, marking another triumph in its long-running fight against the pharmaceutical giant.
A federal judge this week granted Emisphere Technologies Inc.’s oral GPL patent application and ordered Lilly to assign to Emisphere the patent application filed by Lilly in February 2002.
Lilly had argued that Emisphere’s request for the injunction...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.